IBD: short, randomized trial of low-FODMAP diet yields promising outcomes

  • Bodini G & al.
  • Nutrition
  • 01.07.2019

  • von Emily Willingham, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • In patients with IBD, a brief switch to a low-FODMAP diet (LFD) was tied to reduced inflammatory markers and improved disease activity and QoL measures in this randomized trial.

Why this matters

  • FODMAPs have been implicated in symptoms related to irritable bowel syndrome (IBS), and recent findings have pointed to some benefit of a low FODMAP diet for IBD.

Key results

  • After 6 weeks, disease activity scores decreased with LFD vs standard diet (SD) (P=.024) among those with Crohn’s disease.
  • Median (interquartile range) calprotectin values also decreased in the LFD group from 76.6 (50-286.3) at baseline to 50 (50.6-81) mg/kg at 6 weeks (P=.004).
  • Such a decrease was not seen with SD.
  • Median disease-specific QoL scores increased significantly in the LFD group (P=.05) but did not change with the SD. 

Study design

  • 55 patients with IBD (in remission or with mild activity) were randomly allocated to LFD or SD for 6 weeks.
  • Measures used for disease activity were the Harvey-Bradshaw index (Crohn’s) and partial Mayo score (ulcerative colitis). 
  • Funding: None disclosed.

Limitations

  • Short trial, small numbers enrolled.